Investigator-Initiated Studies

CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in the support for Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they have been designed to treat. CSL Behring also supports innovative clinical and basic science studies that address important medical and scientific questions related to our therapeutic areas of focus.

The CSL Behring IIS program is open to physicians, researchers and institutions interested in conducting their own research. We receive many requests for support and carefully evaluate each one with priority given to proposals that align with our interests.

Learn more About CSL Behring IIS